Mga Batayang Estadistika
| LEI | M2XHYMU3TZNEZURC6H66 |
| CIK | 927066 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DaVita Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 20, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E |
|
| August 5, 2025 |
DaVita Inc. 2nd Quarter 2025 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 2nd Quarter 2025 Results Denver, Colorado, August 5, 2025 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2025. “We’re reporting another solid quarter, fueled by our unwavering focus on patient care,” said Javier Rodriguez, CEO of DaVita Inc. “We continued to deliver exceptional cli |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 51 |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 5, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| July 17, 2025 |
EX-10.1 Exhibit 10.1 Execution Version SEVENTH AMENDMENT dated as of July 17, 2025 (this “Amendment”), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto and Wells Fargo Bank, National Association, as Administrative Agent. RECITALS A. The Borrower, the Lenders party thereto from time to time, the |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR [] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-14106 A. Full title of the plan and the add |
|
| June 9, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 5, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 23, 2025 |
Exhibit 4.1 DAVITA INC., as Issuer, the GUARANTORS named herein, as Guarantors, and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 23, 2025 6.750% Senior Notes due 2033 TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitions 19 SECTION 1.03. Incorporation by Reference of TIA 20 SECTION 1 |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 20, 2025 |
DaVita Inc. Announces Offering of $750 Million Senior Notes Exhibit 99.1 DaVita Inc. Announces Offering of $750 Million Senior Notes DENVER, May 20, 2025 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today that it has commenced a private offering (the “offering”) of $750 million aggregate principal amount of its senior notes due 2033 (the “2033 notes”), subject to market and other conditions. DaVita intends to use the net proceeds from the |
|
| May 20, 2025 |
DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering Exhibit 99.1 DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering DENVER, May 20, 2025 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today the upsize and pricing of its previously announced private offering (the “offering”) of its 6.750% senior notes due 2033 (the “2033 notes”). The aggregate principal amount of the 2033 notes offered in the offering was in |
|
| May 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 12, 2025 |
DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan Exhibit 10.3 DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan This Stock Appreciation Rights Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Terms Gra |
|
| May 12, 2025 |
DaVita Inc. 1st Quarter 2025 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 1st Quarter 2025 Results Denver, Colorado, May 12, 2025 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2025. “Our strong first quarter performance demonstrates the stability and consistency of our operating model” said Javier Rodriguez, CEO of DaVita Inc. “We maintain a steadfast |
|
| May 12, 2025 |
DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan Exhibit 10.2 DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Terms Grantee: «G |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 12, 2025 |
Exhibit 10.1 DaVita Inc. Performance-Based Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Performance-Based Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (th |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 5 |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) X Defini |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 12, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| February 13, 2025 |
DaVita Inc. 4th Quarter 2024 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 4th Quarter 2024 Results Denver, Colorado, February 13, 2025 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended December 31, 2024. “Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance rang |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. (Exact name of |
|
| February 13, 2025 |
Exhibit 19.1 1.PURPOSE To provide guidelines to directors, executive officers and teammates (including temporary and provisional teammates and independent contractors) (collectively “teammates”) of DaVita Inc. (the “Company”) or any of its subsidiaries regarding transactions involving Company Securities (as defined below) or securities of third parties (“Third-Party Securities”). It is the Company |
|
| February 13, 2025 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY as of December 31, 2024 Name Jurisdiction of Organization Aberdeen Dialysis, LLC Delaware Adair Dialysis, LLC Delaware Afton Dialysis, LLC Delaware Ahern Dialysis, LLC Delaware Alenes Dialysis, LLC Delaware Alomie Dialysis, LLC Delaware Alterra Dialysis, LLC Delaware American Fork Dialysis, LLC Delaware American Medical Insurance, Inc. Arizona Amery Dialysi |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 13, 2025 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 13, 2025 |
Exhibit 10.6 FIFTH AMENDMENT dated as of August 7, 2024 (this “Amendment”), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the “Borrower”), the other Loan Parties party hereto, each Lender party hereto and Wells Fargo Bank, National Association, as Administrative Agent. RECITALS A. The Borrower, the Lenders party thereto from time to time, the other parties thereto and |
|
| October 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 29, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 29, 2024 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Dela |
|
| October 29, 2024 |
DaVita Inc. 3rd Quarter 2024 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 3rd Quarter 2024 Results Denver, Colorado, October 29, 2024 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. “We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance,” said Javier Rodrigu |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 9, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| September 13, 2024 |
Employment Agreement between David Maughan and DaVita Inc., effective as of September 15, 2024. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made effective as of September 15, 2024 (the “Effective Date”), by and between DaVita Inc., a Delaware corporation (the “Company”) and David Maughan (“Employee”). WHEREAS, the Company desires to appoint Employee as Chief Operating Officer, Kidney Care, and Employee desires to serve in such position, upon the terms an |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 5, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| September 5, 2024 |
AMENDED AND RESTATED BYLAWS DAVITA INC., a Delaware corporation Dated as of September 5, 2024 Exhibit 3.1 AMENDED AND RESTATED BYLAWS for DAVITA INC., a Delaware corporation Dated as of September 5, 2024 INDEX ARTICLE I CORPORATE PURPOSE Section 1. General Purpose ARTICLE II OFFICES Section 1. Principal Office Section 2. Other Offices ARTICLE III STOCKHOLDERS Section 1. Place of Meetings; Remote Meetings Section 2. Annual Meeting Section 3. Organization Section 4. Action Without a Meeting |
|
| August 14, 2024 |
Exhibit 4.1 DAVITA INC., as Issuer, the GUARANTORS named herein, as Guarantors, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of August 13, 2024 6.875% Senior Notes due 2032 TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitions 19 SECTION 1.03. Incorporation by Reference of TIA |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 14, 2024 |
Exhibit 10.1 SIXTH AMENDMENT dated as of August 13, 2024 (this “Amendment”), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the “Borrower”), the other Loan Parties party hereto, each Incremental Tranche A-1 Term Lender (as defined below), each other Lender party hereto and Wells Fargo Bank, National Association, as Administrative Agent. RECITALS A. The Borrower, the Len |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 9, 2024 |
DaVita Inc. Announces Pricing of $1.0 Billion Senior Notes Offering Exhibit 99.1 DaVita Inc. Announces Pricing of $1.0 Billion Senior Notes Offering DENVER, August 8, 2024 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today the pricing of its previously announced private offering (the “offering”) of $1.0 billion aggregate principal amount of its 6.875% senior notes due 2032 (the “2032 notes”). The 2032 notes were priced at 100.000% of their face a |
|
| August 8, 2024 |
DaVita Inc. Announces Offering of $1.0 Billion Senior Notes Exhibit 99.1 DaVita Inc. Announces Offering of $1.0 Billion Senior Notes DENVER, August 8, 2024 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today that it has commenced a private offering (the “offering”) of $1.0 billion aggregate principal amount of its senior notes due 2032 (the “2032 notes”), subject to market and other conditions. DaVita intends to use the net proceeds from t |
|
| August 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 8, 2024 |
DVA / DaVita Inc. / BERKSHIRE HATHAWAY INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 51 |
|
| August 6, 2024 |
DaVita Inc. 2nd Quarter 2024 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 2nd Quarter 2024 Results Denver, Colorado, August 6, 2024 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2024. “On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita,” said Javier |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| July 12, 2024 |
FOIA Confidential Treatment Request by DaVita Inc. Pursuant to Rule 83 (17 C.F.R. §200.83). This letter requests confidential treatment of the bracketed portions of this letter (designated by “[***]”) July 12, 2024 FOIA CONFIDENTIAL TREATMENT REQUESTED BY DAVITA INC. PURSUANT TO 17 C.F.R. §200.83 (“Rule 83”) (Contact: Christopher Berry, Chief Accounting Officer, (253) 733-4638) U.S. Securities and |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR [] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-14106 A. Full title of the plan and the add |
|
| June 10, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 13, 2024 |
Exhibit 10.1 FOURTH AMENDMENT dated as of May 9, 2024 (this “Amendment”), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the “Borrower”), the other Loan Parties party hereto, each of the Converting Tranche B-1 Term Lenders (as defined below) party hereto, each Additional Extended Tranche B-1 Term Lender (as defined below) and Wells Fargo Bank, National Association, as A |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emplo |
|
| May 10, 2024 |
FOIA Confidential Treatment Request by DaVita Inc. Pursuant to Rule 83 (17 C.F.R. §200.83). This letter requests confidential treatment of the bracketed portions of this letter (designated by “[***]”). May 10, 2024 FOIA CONFIDENTIAL TREATMENT REQUESTED BY DAVITA INC. PURSUANT TO 17 C.F.R. §200.83 (“Rule 83”) (Contact: Christopher Berry, Chief Accounting Officer, (253) 733-4638) U.S. Securities and |
|
| May 2, 2024 |
Exhibit 10.1 DaVita Inc. Performance-Based Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Performance-Based Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (th |
|
| May 2, 2024 |
DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan Exhibit 10.3 DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan This Stock Appreciation Rights Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Terms Gra |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 5 |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emplo |
|
| May 2, 2024 |
DaVita Inc. 1st Quarter 2024 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 1st Quarter 2024 Results Denver, Colorado, May 2, 2024 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2024. “Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to inve |
|
| May 2, 2024 |
DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan Exhibit 10.2 DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Terms Grantee: «G |
|
| May 1, 2024 |
DAVITA INC. 2000 16th Street Denver, CO 80202 Exhibit 10.1 DAVITA INC. 2000 16th Street Denver, CO 80202 April 30, 2024 Berkshire Hathaway Inc. 3555 Farnam Street Omaha, NE 68131 Ladies and Gentlemen: This letter agreement (this “Share Repurchase Agreement”) is made by and between Berkshire Hathaway Inc. and its Affiliates (collectively, “Investor”) and DaVita Inc. (the “Company”). Whereas, Investor has beneficial ownership of a significant p |
|
| May 1, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 30, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) X Defini |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 6, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| February 16, 2024 |
DVA / DaVita Inc. / BERKSHIRE HATHAWAY INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 14, 2024 |
DAVITA INC. DODD-FRANK POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Exhibit 97.1 DAVITA INC. DODD-FRANK POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Board of Directors (the “Board”) of DaVita Inc. (the “Company”) has adopted this Dodd-Frank Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company. Th |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. (Exact name of |
|
| February 14, 2024 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY as of December 31, 2023 Name Jurisdiction of Organization Aberdeen Dialysis, LLC Delaware Adair Dialysis, LLC Delaware Afton Dialysis, LLC Delaware Ahern Dialysis, LLC Delaware Alenes Dialysis, LLC Delaware Alomie Dialysis, LLC Delaware Alterra Dialysis, LLC Delaware American Fork Dialysis, LLC Delaware American Medical Insurance, Inc. Arizona Amery Dialysi |
|
| February 14, 2024 |
MIRO / Miromatrix Medical Inc / DAVITA INC. - SC 13G/A Passive Investment SC 13G/A 1 miromatrixmedicalinc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Miromatrix Medical Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 60471P108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this St |
|
| February 13, 2024 |
DVA / DaVita Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: DaVita Inc Title of Class of Securities: Common Stock CUSIP Number: 23918K108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| February 13, 2024 |
DaVita Inc. 4th Quarter 2023 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 4th Quarter 2023 Results Denver, Colorado, February 13, 2024 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2023. “As we reflect on the past year, our 2023 financial performance highlighted the resilience of our business,” said Javier Rodriguez, CEO of DaVita Inc. “The |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 13, 2024 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| November 7, 2023 |
DaVita Inc. 3rd Quarter 2023 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 3rd Quarter 2023 Results Denver, Colorado, November 7, 2023 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2023. "We delivered another strong quarter," said Javier Rodriguez, CEO of DaVita Inc. "We began the year by making progress earlier than expected across many of our key |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delawa |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| August 3, 2023 |
DaVita Inc. 2nd Quarter 2023 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 2nd Quarter 2023 Results Denver, Colorado, August 3, 2023 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2023. "Over the first half of the year, DaVita has been focused on innovation in our clinical systems and driving operational improvements throughout our organization," said Jav |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 3, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 51 |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 19, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 12, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR [] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissions file number 1-14106 A. Full title of the plan and the ad |
|
| June 8, 2023 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DAVITA INC. Pursuant to Section 242 and 245 of the Delaware General Corporation Law DaVita Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), does hereby certify: FIRST: That the name of the Corporation is |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 5 |
|
| May 8, 2023 |
Exhibit 10.4 SECOND AMENDMENT dated as of April 3, 2023 (this “Amendment”), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the “Borrower”), and Wells Fargo Bank, National Association, as Administrative Agent. RECITALS A. The Borrower, the Lenders party thereto from time to time, the other parties thereto and Wells Fargo Bank, National Association, as Administrative Agen |
|
| May 8, 2023 |
DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan Exhibit 10.3 DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Terms Grantee: «G |
|
| May 8, 2023 |
DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan Exhibit 10.1 DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan This Stock Appreciation Rights Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Terms Gra |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emplo |
|
| May 8, 2023 |
Exhibit 10.2 DaVita Inc. Performance-Based Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Performance-Based Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (th |
|
| May 8, 2023 |
DaVita Inc. 1st Quarter 2023 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 1st Quarter 2023 Results Denver, Colorado, May 8, 2023 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2023. “In the first quarter, we performed well on our key metrics and our results benefited from an improving macro environment,” said Javier Rodriguez, CEO of DaVita Inc. “While |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 28, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| May 1, 2023 |
Exhibit 10.1 THIRD AMENDMENT dated as of April 28, 2023 (this “Amendment”), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto and Wells Fargo Bank, National Association, as Administrative Agent. RECITALS A. The Borrower, the Lenders party thereto from time to time, the other parties thereto and |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) X Defini |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: X Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 15, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| February 22, 2023 |
DAVITA INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of January 1, 2023) ARTICLE I Exhibit 10.14 DAVITA INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of January 1, 2023) ARTICLE I PURPOSE The primary purposes of the DaVita Inc. (the “Company”) Non-Employee Director Compensation Policy (this “Policy”) are as follows: •to pay differentially higher compensation for higher levels of work, responsibility and performance; •to provide a compensation structure that will a |
|
| February 22, 2023 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY as of December 31, 2022 Name Jurisdiction of Organization Aberdeen Dialysis, LLC Delaware Accountable Kidney Care, LLC Delaware Adair Dialysis, LLC Delaware Afton Dialysis, LLC Delaware Ahern Dialysis, LLC Delaware Alenes Dialysis, LLC Delaware Alomie Dialysis, LLC Delaware Alterra Dialysis, LLC Delaware American Fork Dialysis, LLC Delaware American Medical |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2023 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 22, 2023 |
DaVita Inc. Performance Award Agreement under the DaVita Inc. 2020 Incentive Award Plan Exhibit 10.31 DaVita Inc. Performance Award Agreement under the DaVita Inc. 2020 Incentive Award Plan This Performance Award Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Terms Grantee: «Grantee» |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. (Exact name of |
|
| February 22, 2023 |
DaVita Inc. 4th Quarter 2022 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 4th Quarter 2022 Results Denver, Colorado, February 22, 2023 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2022. “We continue to have excitement and conviction in our long-term capabilities and strategy to differentiate DaVita as a healthcare provider and employer of |
|
| February 14, 2023 |
US7743743004 / Rockwell Medical Inc / DAVITA INC. - SC 13G/A Passive Investment SC 13G/A 1 dva-formsc13garockwellmedi.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Rockwell Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 774374300 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this St |
|
| February 9, 2023 |
DVA / DaVita HealthCare Partners Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0712-davitainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: DaVita Inc. Title of Class of Securities: Common Stock CUSIP Number: 23918K108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pur |
|
| October 31, 2022 |
AMENDMENT NO. 1 TO AGREEMENT NO. 00135085 BETWEEN AMGEN USA INC. AND DAVITA INC. Note: Certain identified information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delawa |
|
| October 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 28, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 28, 2022 |
DaVita Inc. 3rd Quarter 2022 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 3rd Quarter 2022 Results Denver, Colorado, October 28, 2022 ? DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2022. "The third quarter was a challenging quarter for us. Like others in the healthcare community, negative volume trends due to COVID and continued labor pressure impac |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 14, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 18, 2022 |
AMENDED AND RESTATED BYLAWS for DAVITA INC., a Delaware corporation Dated as of October 14, 2022 Exhibit 3.1 AMENDED AND RESTATED BYLAWS for DAVITA INC., a Delaware corporation Dated as of October 14, 2022 INDEX ARTICLE I CORPORATE PURPOSE Section 1. General Purpose ARTICLE II OFFICES Section 1. Principal Office Section 2. Other Offices ARTICLE III STOCKHOLDERS Section 1. Place of Meetings; Remote Meetings Section 2. Annual Meeting Section 3. Organization Section 4. Action Without a Meeting S |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 8, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| August 3, 2022 |
DVA / DaVita HealthCare Partners Inc. / BERKSHIRE HATHAWAY INC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| August 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 1, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 51 |
|
| August 1, 2022 |
DaVita Inc. 2nd Quarter 2022 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 2nd Quarter 2022 Results Denver, Colorado, August 1, 2022 ? DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2022. ?We are living in a dynamic time with a sustained global pandemic, labor shortage, supply chain disruption, and more. Despite all this, my confidence in our business and o |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR [] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissions file number 1-14106 A. Full title of the plan and the ad |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 9, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 25, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant X Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emplo |
|
| May 5, 2022 |
DaVita Inc. 1st Quarter 2022 Results Contact: Investor Relations DaVita Inc. [email protected] DaVita Inc. 1st Quarter 2022 Results Denver, Colorado, May 5, 2022 ? DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2022. For the quarter, diluted earnings per share was $1.61, a decrease of (10.1)% from the prior quarter. First quarter 2022 diluted earnings per share was impacted by continued |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 5 |
|
| April 29, 2022 |
Rationale to vote FOR the Proposal and Rebuttal to Company’s Opposition Statement 1 NAME OF REGISTRANT: DAVITA INC. NAME OF PERSON RELYING ON EXEMPTION: FRIENDS FIDUCIARY CORPORATION ADDRESS OF PERSON RELYING ON EXEMPTION: 1700 MARKET STREET, SUITE 1535, PHILADELPHIA, PA 19103 April 29, 2022 To DaVita Stockholders: Friends Fiduciary Corporation seeks your support for Proposal 4 at the stockholder meeting on June 9, 2022. The proposal asks DaVita to prepare an annual report on i |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) X Defini |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 18, 2022 |
RMTI / Rockwell Medical Inc / DAVITA INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Rockwell Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 774374102 (CUSIP Number) April 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the Rule Pursuant to Which |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 6, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| February 14, 2022 |
DVA / DaVita HealthCare Partners Inc. / BERKSHIRE HATHAWAY INC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. (Exact name of |
|
| February 11, 2022 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY as of December 31, 2021 Name Jurisdiction of Organization Aberdeen Dialysis, LLC Delaware Accountable Kidney Care, LLC Delaware Ahern Dialysis, LLC Delaware AI Care Insights, LLC Delaware Alenes Dialysis, LLC Delaware American Fork Dialysis, LLC Delaware American Medical Insurance, Inc. Arizona Amity Dialysis, LLC Delaware Animas Dialysis, LLC Delaware Arca |
|
| February 11, 2022 |
MIRO / Miromatrix Medical Inc. / DAVITA INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 60471P108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the Rule Pursuant to |
|
| February 10, 2022 |
DaVita Inc. 4th Quarter 2021 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 4th Quarter 2021 Results Denver, Colorado, February 10, 2022 ? DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2021. ?COVID continues to evolve and have a direct impact on our world, especially on the healthcare system?, said Javier Rodriguez, CEO of DaVita |
|
| February 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 9, 2022 |
DAVITA INC. 2000 16th Street Denver, CO 80202 DAVITA INC. 2000 16th Street Denver, CO 80202 February 9, 2022 Berkshire Hathaway Inc. 3555 Farnam Street Omaha, NE 68131 Ladies and Gentlemen: Reference is hereby made to that letter agreement, dated as of May 7, 2013, by and between DaVita Inc. (the ?Company?) and Berkshire Hathaway Inc. and its Affiliates (collectively, ?Investor? and such letter agreement, the ?Original Agreement?). For purpos |
|
| February 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 9, 2022 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 9, 2022 |
DVA / DaVita HealthCare Partners Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: DaVita Inc. Title of Class of Securities: Common Stock CUSIP Number: 23918K108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 17, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 28, 2021 |
DaVita Inc. 3rd Quarter 2021 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 3rd Quarter 2021 Results Denver, Colorado, October 28, 2021 ? DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2021. "The third quarter was another strong quarter for DaVita in the face of a challenging operating environment," said Javier Rodriguez, CEO of DaVita In |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 28, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delawa |
|
| October 28, 2021 |
DAVITA INC. SEVERANCE PLAN FOR DIRECTORS AND ABOVE Exhibit 10.1 DAVITA INC. SEVERANCE PLAN FOR DIRECTORS AND ABOVE DaVita Inc., a Delaware corporation (the ?Company?), restates the DaVita Inc. Severance Plan for Directors and Above (this ?Plan?), effective August 13, 2021, for the benefit of certain Teammates (as defined in Section 1(h)) of the Company and its subsidiaries. This Plan is intended to secure the continued services and ensure the cont |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 9, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| August 4, 2021 |
DVA / DaVita HealthCare Partners Inc. / BERKSHIRE HATHAWAY INC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| August 3, 2021 |
DaVita Inc. 2nd Quarter 2021 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 2nd Quarter 2021 Results Denver, Colorado, August 3, 2021 ? DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2021. For the quarter, diluted earnings per share from continuing operations was $2.64, an increase of 63.0% from the prior year diluted earnings per share from c |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 51 |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 3, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissions file number 1-14106 A.Full title of the plan and the address of the plan, if different fro |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 19, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 18, 2021 |
Rationale to vote FOR the Proposal and Rebuttal to Company’s Opposition Statement NAME OF REGISTRANT: DAVITA NAME OF PERSON RELYING ON EXEMPTION: FRIENDS FIDUCIARY CORPORATION ADDRESS OF PERSON RELYING ON EXEMPTION: 1700 MARKET STREET, SUITE 1535, PHILADELPHIA, PA 19103 May 18, 2021 To DaVita Stockholders: Friends Fiduciary Corporation seeks your support for Proposal 4 at the stockholder meeting on June 10, 2021. |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 29, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| April 29, 2021 |
DaVita Inc. 1st Quarter 2021 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 1st Quarter 2021 Results Denver, Colorado, April 29, 2021 ? DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2021. For the quarter, diluted earnings per share from continuing operations was $2.09, an increase of 15.5% from the prior year diluted earnings per share from |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 5 |
|
| April 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant X Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 23, 2021 |
- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant X Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 9, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 26, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 25, 2021 |
DaVita Inc. Announces Upsize and Pricing of Add-On Offering of $1 Billion Senior Notes EXHIBIT 99.1 DaVita Inc. Announces Upsize and Pricing of Add-On Offering of $1 Billion Senior Notes DENVER, Feb. 24, 2021 /PRNewswire/ - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today the upsize and pricing of its previously announced private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030 (the “notes”). The principal amount of the notes w |
|
| February 24, 2021 |
DaVita Inc. Announces Add-On Offering of $750 Million Senior Notes EXHIBIT 99.1 DaVita Inc. Announces Add-On Offering of $750 Million Senior Notes DENVER, Feb. 24, 2021 /PRNewswire/ - DaVita Inc. (NYSE: DVA) (?DaVita?) announced today that it has commenced a private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030 (the ?notes?), subject to market and other conditions. The notes will be issued as additional not |
|
| February 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 16, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. (Exact name of |
|
| February 12, 2021 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY as of December 31, 2020 Name Jurisdiction of Organization Aberdeen Dialysis, LLC Delaware Adair Dialysis, LLC Delaware Alenes Dialysis, LLC Delaware American Fork Dialysis, LLC Delaware American Medical Insurance, Inc. Arizona Animas Dialysis, LLC Delaware Arcadia Gardens Dialysis, LLC Delaware Arrowhead Dialysis, LLC Delaware Attell Dialysis, LLC Delaware |
|
| February 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 11, 2021 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| February 11, 2021 |
DaVita Inc. 4th Quarter 2020 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 4th Quarter 2020 Results Denver, Colorado, February 11, 2021 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2020. For the full year diluted earnings per share from continuing operations was $6.39, an increase of 38.9% from the prior year, and adjusted di |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: DaVita Inc. Title of Class of Securities: Common Stock CUSIP Number: 23918K108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| December 10, 2020 |
AMENDED AND RESTATED BYLAWS for DAVITA INC., a Delaware corporation Dated as of December 10, 2020 EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS for DAVITA INC., a Delaware corporation Dated as of December 10, 2020 INDEX ARTICLE I CORPORATE PURPOSE Section 1. General Purpose ARTICLE II OFFICES Section 1. Principal Office Section 2. Other Offices ARTICLE III STOCKHOLDERS Section 1. Place of Meetings; Remote Meetings Section 2. Annual Meeting Section 3. Organization Section 4. Action Without a Meeting |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 9, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| November 13, 2020 |
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE EXHIBIT 99.2 EXHIBIT A-1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE In re DaVITA INC. STOCKHOLDER DERIVATIVE LITIGATION This Document Relates To: ALL ACTIONS. ) ) ) ) ) ) ) ) Civil Action No. 1:17-cv-00152-MPT NOTICE OF PROPOSED DERIVATIVE SETTLEMENT TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF THE COMMON STOCK OF DAVITA, INC. (“DAVITA” OR THE “COMPANY”) AS OF OCTOBER 23, |
|
| November 13, 2020 |
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE EXHIBIT 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE In re DaVITA, INC. STOCKHOLDER DERIVATIVE LITIGATION This Document Relates To: ALL ACTIONS. ) ) ) ) ) ) ) ) Case No. 1:17-cv-00152-MPT STIPULATION OF SETTLEMENT This Stipulation of Settlement, dated October 23, 2020 (“Stipulation” or “Settlement”), is made and entered into by and among the following parties, and by and t |
|
| November 13, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 29, 2020 |
DaVita Inc. 3rd Quarter 2020 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 3rd Quarter 2020 Results Denver, Colorado, October 29, 2020 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the third quarter ended September 30, 2020. During the quarter, notwithstanding the challenges of responding to COVID-19, the Company delivered strong financial and operating results, and |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 29, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delawa |
|
| October 29, 2020 |
Exhibit 10.4 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) is executed by DaVita Inc. (“Parent”), on its own behalf and on behalf of its subsidiaries and affiliates (collectively, "Employer") and LeAnne Zumwalt (the “Employee”) on this 1st day of October, 2020 (collectively referred to herein as “Parties” and each individually, a “Party”). 1.Background. The Parties have discuss |
|
| October 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 1, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E |
|
| September 21, 2020 |
DVA / DaVita HealthCare Partners Inc. / BERKSHIRE HATHAWAY INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| September 17, 2020 |
DAVITA ANNOUNCES FINAL RESULTS OF SELF-TENDER OFFER EX-99.(a)(5)(C) Exhibit (a)(5)(C) DAVITA ANNOUNCES FINAL RESULTS OF SELF-TENDER OFFER DENVER, CO, September 17, 2020 – DAVITA INC. (NYSE: DVA) (“DaVita”) a health care provider focused on transforming care delivery to improve quality of life for patients globally and one of the largest providers of kidney care services in the United States, announced today the final results of its modified “Dutch |
|
| September 17, 2020 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4 – Final Amendment) DaVita Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 23918K108 (CUSIP Number of Class of |
|
| September 15, 2020 |
DAVITA ANNOUNCES PRELIMINARY RESULTS OF SELF-TENDER OFFER EX-99.(a)(5)(B) Exhibit (a)(5)(B) DAVITA ANNOUNCES PRELIMINARY RESULTS OF SELF-TENDER OFFER DENVER, CO, September 15, 2020 – DAVITA INC. (NYSE: DVA) (“DaVita”), a health care provider focused on transforming care delivery to improve quality of life for patients globally and one of the largest providers of kidney care services in the United States, announced today the preliminary results of its mod |
|
| September 15, 2020 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) DaVita Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 23918K108 (CUSIP Number of Class of Securities) Kathle |
|
| September 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 7, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| September 8, 2020 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DaVita Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 23918K108 (CUSIP Number of Class of Securities) Kathle |
|
| August 27, 2020 |
CORRESP SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SUITE 2000 SAN FRANCISCO, CA 94104 +1 415 772 1200 +1 415 772 7400 FAX AMERICA • ASIA PACIFIC • EUROPE August 27, 2020 Via EDGAR and Email United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 27, 2020 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DaVita Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 23918K108 (CUSIP Number of Class of Securities) Kathle |
|
| August 17, 2020 |
EX-(a)(1)(A) Table of Contents Exhibit (a)(1)(A) DaVita Inc. Offer to Purchase for Cash Shares of its Common Stock for an Aggregate Purchase Price of no More Than $1.0 Billion At a Purchase Price Not Less Than $77.00 Per Share and Not More Than $88.00 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON SEPTEMBER 14 |
|
| August 17, 2020 |
DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan EX-(d)(31) Exhibit (d)(31) DaVita Inc. Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan This Stock Appreciation Rights Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Pri |
|
| August 17, 2020 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File |
|
| August 17, 2020 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) Delaware 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 17, 2020 |
EX-(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL TO TENDER SHARES OF COMMON STOCK OF DAVITA INC. |
|
| August 17, 2020 |
EX-(a)(1)(E) Exhibit (a)(1)(E) DAVITA INC. Offer to Purchase for Cash Up to $1,000,000,000 of Shares of its Common Stock At a Purchase Price Not Less Than $77.00 Per Share and Not More Than $88.00 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON SEPTEMBER 14, 2020, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIM |
|
| August 17, 2020 |
EX-(a)(1)(F) Exhbit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of common stock of DaVita Inc. |
|
| August 17, 2020 |
EX-(a)(1)(D) Exhibit (a)(1)(D) DAVITA INC. Offer to Purchase for Cash Up to $1,000,000,000 of Shares of its Common Stock At a Purchase Price Not Less Than $77.00 Per Share and Not More Than $88.00 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON SEPTEMBER 14, 2020, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIM |
|
| August 17, 2020 |
DAVITA COMMENCES SELF-TENDER OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK EX-(a)(5)(A) Exhibit (a)(5)(A) DAVITA COMMENCES SELF-TENDER OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK DENVER, CO, August 17, 2020 – DAVITA INC. |
|
| August 17, 2020 |
EX-(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY (Not to be used for Signature Guarantee) for Tender of Shares of Common Stock of DAVITA INC. |
|
| August 17, 2020 |
EMAIL COMMUNICATION TO EMPLOYEES OF DAVITA INC. AND ITS SUBSIDIARIES DAVITA INC. TENDER OFFER EX-(a)(1)(G) Exhibit (a)(1)(G) EMAIL COMMUNICATION TO EMPLOYEES OF DAVITA INC. AND ITS SUBSIDIARIES DAVITA INC. TENDER OFFER August 17, 2020 Earlier today, DaVita Inc. (“DaVita”) announced a tender offer to purchase for cash shares of its common stock, par value $0.001 per share (“shares”), for an aggregate purchase price of up to $1.0 billion at a price per share of not less than $77.00 and not m |
|
| August 17, 2020 |
EX-(a)(1)(H) Exhibit (a)(1)(h) DAVITA INC. NOTICE TO CERTAIN HOLDERS OF STOCK-SETTLED STOCK APPRECIATION RIGHTS RE: OFFER TO PURCHASE SHARES OF DAVITA INC. COMMON STOCK August 17, 2020 As you may already know, DaVita Inc. (the “Company”) has recently announced a tender offer (the “Tender Offer”) to purchase for cash shares of its common stock, par value $0.001 per share (the “shares”), having an a |
|
| August 17, 2020 |
SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DaVita Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.001 par value (Title of Class of Securities) 23918K108 (CUSIP Number of Class of Securities) Kathleen A. Waters Chief L |
|
| August 17, 2020 |
DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan EX-(d)(33) Exhibit (d)(33) DaVita Inc. Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive Award Plan (the “Plan”). Primary Ter |
|
| August 17, 2020 |
EX-(d)(32) Exhibit (d)(32) DaVita Inc. Performance-Based Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan This Performance-Based Restricted Stock Unit Agreement (this “Agreement”) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the “Company”), and the Grantee indicated below pursuant to the DaVita Inc. 2020 Incentive |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 11, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 10, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E |
|
| August 11, 2020 |
DAVITA INC., as Issuer, the GUARANTORS named herein, as Guarantors, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of August 11, 2020 3.750% Senior Notes due 2031 TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Definitions. SECTION 1.02. Other Definitions. SECTION 1.03. Incorporation by Reference of TIA. SECTION 1.04. Rules |
|
| August 7, 2020 |
DaVita Inc. Announces Pricing of $1.5 Billion Senior Notes Offering Exhibit 99.1 DaVita Inc. Announces Pricing of $1.5 Billion Senior Notes Offering DENVER, August 6, 2020 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today the pricing of its previously announced private offering of $1.5 billion aggregate principal amount of senior notes due 2031 (the “2031 notes”). The 2031 notes were priced at 100% of their face amount to yield a 3.750% coupon. |
|
| August 7, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| August 6, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| August 6, 2020 |
DaVita Inc. Announces Offering of $1.5 Billion Senior Notes Exhibit 99.1 DaVita Inc. Announces Offering of $1.5 Billion Senior Notes DENVER, August 6, 2020 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today that it has commenced a private offering of $1.5 billion aggregate principal amount of senior notes due 2031 (the “2031 notes”), subject to market and other conditions. Prior to the closing date of this offering, DaVita will deliver a |
|
| July 30, 2020 |
DaVita Inc. 2nd Quarter 2020 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 2nd Quarter 2020 Results Denver, Colorado, July 30, 2020 — During the second quarter of 2020, DaVita (NYSE: DVA) remained focused on its top priorities, the safety and care of its patients, caregivers, teammates and physician partners. In the face of the novel coronavirus (COVID-19) pandemic, we continue to work colla |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 51 |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| July 30, 2020 |
AMENDMENT TO STOCK APPRECIATION RIGHTS AGREEMENTS EXHIBIT 10.1 AMENDMENT TO STOCK APPRECIATION RIGHTS AGREEMENTS This Amendment to Stock Appreciation Rights Agreements is entered into effective as of June 11, 2020, by and between DaVita Inc., a Delaware corporation (the “Company”), and William L. Roper, M.D. (the “Grantee”). WHEREAS, as part of the Grantee’s annual compensation from the Company for his service as a non-employee member of the Boar |
|
| July 23, 2020 |
As filed with the Securities and Exchange Commission on July 22, 2020 Registration No. |
|
| June 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissions file number 1-14106 A.Full title of the plan and the address of the plan, if different fro |
|
| June 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 11, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emp |
|
| June 15, 2020 |
As filed with the Securities and Exchange Commission on June 15, 2020 Registration No. |
|
| June 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| June 9, 2020 |
EXHIBIT 4.1 DAVITA INC., as Issuer, the GUARANTORS named herein, as Guarantors, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of June 9, 2020 4.625% Senior Notes due 2030 TABLE OF CONTENTS ARTICLE ONE DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Definitions. SECTION 1.02. Other Definitions. SECTION 1.03. Incorporation by Reference of TIA. SECTION 1. |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| May 27, 2020 |
DaVita Inc. Announces Pricing of $1.75 Billion Senior Notes Offering EXHIBIT 99.1 DaVita Inc. Announces Pricing of $1.75 Billion Senior Notes Offering DENVER, May 26, 2020 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today the pricing of its previously announced private offering of $1.75 billion aggregate principal amount of senior notes due 2030 (the “2030 notes”). The 2030 notes were priced at 100% of their face amount to yield a 4.625% coupon. |
|
| May 27, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 26, 2020 |
DaVita Inc. Announces Offering of $1.75 Billion Senior Notes EXHIBIT 99.1 DaVita Inc. Announces Offering of $1.75 Billion Senior Notes DENVER, May 26, 2020 (BUSINESS WIRE) - DaVita Inc. (NYSE: DVA) (“DaVita”) announced today that it has commenced a private offering of $1.75 billion aggregate principal amount of senior notes due 2030 (the “2030 notes”), subject to market and other conditions. Prior to the closing date of this offering, DaVita will deliver a |
|
| May 26, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. Delaware 5 |
|
| May 5, 2020 |
DAVITA INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective May 1, 2020) ARTICLE I EXHIBIT 10.1 DAVITA INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective May 1, 2020) ARTICLE I PURPOSE The primary purposes of the DaVita Inc. (the “Company”) Non-Employee Director Compensation Policy (this “Policy”) are as follows: • to pay differentially higher compensation for higher levels of work, responsibility and performance; • to provide a compensation structure that will attract hi |
|
| May 5, 2020 |
DaVita Inc. COVID-19 Response Efforts and 1st Quarter 2020 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. COVID-19 Response Efforts and 1st Quarter 2020 Results Denver, Colorado, May 5, 2020 — During the first quarter of 2020, DaVita Inc. (NYSE: DVA) took significant steps to respond to the novel coronavirus (COVID-19) pandemic while continuing to provide high-quality care for its patients whose lives depend on receiving |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emplo |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) X Defini |
|
| April 13, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 13, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| April 13, 2020 |
DaVita Inc. Provides Commentary on the COVID-19 Pandemic EXHIBIT 99.1 DaVita Inc. Provides Commentary on the COVID-19 Pandemic DENVER (April 13, 2020) - DaVita Inc., a leading provider of kidney care services, today provided the following commentary regarding the COVID-19 pandemic. Clinical and operating response to COVID-19 As a caregiving organization, DaVita is focused on the well-being of its patients, caregivers, and physician partners. In this tim |
|
| March 23, 2020 |
EXHIBIT 99.1 DaVita Supports 55,000 Teammates amid COVID-19 Crisis Kidney care company gives additional pay to workers caring for their families and patients in trying times DENVER (March 23, 2020) - DaVita Kidney Care today announced it is giving U.S. employees, known as teammates, an extra $100 each week. With many people in the U.S. facing significant hardships, such as loss of household income |
|
| March 23, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 23, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| March 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 10, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em |
|
| February 21, 2020 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DaVita Inc. (the “Company,” “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. The following summary of the material terms of our capital stock is based upon, and qualified by reference to, our |
|
| February 21, 2020 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY as of December 31, 2019 Name Jurisdiction of Organization Aberdeen Dialysis, LLC Delaware Accountable Kidney Care, LLC Delaware Adair Dialysis, LLC Delaware American Fork Dialysis, LLC Delaware American Medical Insurance, Inc. Arizona Animas Dialysis, LLC Delaware Arcadia Gardens Dialysis, LLC Delaware Ashdow Dialysis, LLC Delaware Atlantic Dialysis, LLC De |
|
| February 21, 2020 |
EXHIBIT 10.21 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made effective as of April 29, 2015 (the “Effective Date”), by and between DaVita HealthCare Partners Inc. (“Parent”) and one of its controlled affiliates (“Employer,” and collectively with Parent, “DaVita”) and Michael Staffieri (“Teammate”). In consideration of the mutual covenants and agreements hereinafter set f |
|
| February 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-14106 DAVITA INC. (Exact name of |
|
| February 21, 2020 |
EXHIBIT 10.3 FIRST AMENDMENT dated as of February 13, 2020 (this “Amendment”), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto and Wells Fargo Bank, National Association, as Administrative Agent. RECITALS A. The Borrower, the Lenders party thereto from time to time, the other parties thereto a |
|
| February 12, 2020 |
DVA / DaVita HealthCare Partners Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: DaVita Inc Title of Class of Securities: Common Stock CUSIP Number: 23918K108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| February 10, 2020 |
DaVita Inc. 4th Quarter 2019 Results Contact: Jim Gustafson Investor Relations DaVita Inc. (310) 536-2585 DaVita Inc. 4th Quarter 2019 Results Denver, Colorado, February 10, 2020 — DaVita Inc. (NYSE: DVA) today announced results for the quarter and year ended December 31, 2019. Fourth quarter 2019 highlights: • Consolidated revenues of $2.899 billion. • Operating income of $463 million or 16.0% operating margin. • Diluted earnings pe |
|
| February 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| January 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 23, 2020 DAVITA INC. (Exact name of registrant as specified in its charter) DE 1-14106 51-0354549 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| January 9, 2020 |
DVA / DaVita HealthCare Partners Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| December 6, 2019 |
DVA / DaVita HealthCare Partners Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| December 6, 2019 |
DVA / DaVita HealthCare Partners Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) X Defini |
|
| November 25, 2019 |
DVA / DaVita HealthCare Partners Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: X Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| November 12, 2019 |
DVA / DaVita HealthCare Partners Inc. / Berkshire Hathaway Inc - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
